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Abstract
Background: In invasive malignancies, Dll4/Notch signaling inhibition enhances non-functional vessel proliferation
and limits tumor growth by reducing its blood perfusion.
Methods: To assess the effects of targeted Dll4 allelic deletion in the incipient stages of tumor pathogenesis, we
chemically induced skin papillomas in wild-type and Dll4+/− littermates, and compared tumor growth, their histological
features, vascularization and the expression of angiogenesis-related molecules.
Results: We observed that Dll4 down-regulation promotes productive angiogenesis, although with less mature vessels,
in chemically-induced pre-cancerous skin papillomas stimulating their growth. The increase in endothelial activation
was associated with an increase in the VEGFR2 to VEGFR1 ratio, which neutralized the tumor-suppressive effect of
VEGFR-targeting sorafenib. Thus, in early papillomas, lower levels of Dll4 increase vascularization through raised VEGFR2
levels, enhancing sensitivity to endogenous levels of VEGF, promoting functional angiogenesis and tumor growth.
Conclusion: Tumor promoting effect of low-dosage inhibition needs to be considered when implementing Dll4
targeting therapies.
Background
Delta-like 4 (Dll4)-mediated Notch signaling critically in-
fluences blood vessel formation in both physiological and
pathological settings. During embryonic development, this
signaling is absolutely required for normal arterial specifi-
cation [1]. In addition, Dll4/Notch fundamentally partici-
pates in the regulation of embryonic [1, 2], post-natal
developmental [3–6], regenerative [7] and tumor sprout-
ing angiogenesis [8–14]. It mediates communication be-
tween adjacent endothelial cells (ECs) that lead the sprout
formation and adjacent ECs that, under Dll4/Notch
control, remain in the quiescent state in pre-existing
vasculature or rather proliferate then migrate, forming the
trunk of the new vessel [5, 6, 13]. Mechanistically, Dll4/
Notch enables the selective EC departure from pre-
existing activated endothelium and organized sprout out-
growth by decreasing the VEGFR2/VEGFR1 ratio and
therefore reducing the sensitivity of signal-receiving ECs
to VEGF.
Elevated Dll4 expression predicts poor prognosis in
different cancers [14–17]. Previous studies have shown
that although Dll4/Notch blockade potentiates the tumor-
driven angiogenic response, it inhibits tumor growth due
to the formation of immature and poorly functional
vessels that result in reduced tumor perfusion [8–13, 18].
Additionally, Dll4/Notch inhibition has been found to
reduce the frequency of cancer stem cells [19]. Although
these findings indicate that the Dll4/Notch blockade may
provide an effective way to improve cancer control, the
capacity for normalization of the aberrant vascular net-
work to Dll4/Notch inhibition remains undetermined.
Moreover, therapeutic inhibition of Dll4 signaling may
face important safety limitations since chronic Dll4/Notch
impairment was found to destabilize normal endothelium
giving origin to the formation of benign vascular tumors
[12, 20, 21]. Nevertheless, several studies with different
Dll4 blocking antibodies are now proceeding through
phase I trials.
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Despite the wealth of information regarding the effects
of Dll4/Notch inhibition in invasive neoplasms, little is
known regarding its role in benign and early, pre-
cancerous lesions. We have previously shown that Dll4
heterozygote mice can produce functional neo-
angiogenesis and improve vascular function in the con-
text of physiological angiogenesis [7]. The present study
was undertaken to assess the effects of targeted Dll4 allelic
deletion in the incipient stages of tumor pathogenesis. For
this purpose, we used a classic 7,12-dimethylbenz[a]anthra-
cene (DMBA)/12-O-tetradecanoylphorbol-13-acetate
(TPA)-induced skin carcinogenesis model wherein the initi-
ating carcinogen, DMBA, results in an activating mutation
in the H-ras gene and generation of “initiated” epidermal
cells [22]. These cells form papillomas progressing, in the
later phase, to squamous carcinomas and sharing the same
H-ras mutation with some human lesions, like papillomas
in Costello syndrome and epidermal nevi [23, 24].
Methods
Mice
The CD1 wild-type (WT) and heterozygous Dll4+/− mice
were generated and housed as previously described [1,
12]. The mice were fed standard laboratory diet and
drinking water ad libitum. All animal-involving proce-
dures were approved by the Faculty of Veterinary Medi-
cine of Lisbon Ethics and Animal Welfare Committee
(Approval ID: PTDC/CVT/71084/2012).
Chemically-induced skin tumourigenesis
Male, 8-week old WT and Dll4+/− littermates (n = 12 for
each group) were treated with a single dose of 25 μg of
7,12-dimethylbenz[a]anthracene (DMBA; Sigma, St.
Louis, MO) in 200 μL acetone per mouse applied to
shaved dorsal skin. Beginning a week after DMBA-
induction, tumor onset and growth was promoted by
treating mice twice a week for 19 weeks with 4 μg of 12-
O-tetradecanoylphorbol-13-acetate (TPA; Sigma, St.
Louis, MO) in 100 μL of dimethyl sulfoxide (DMSO) per
mouse. The appearance of skin lesions was monitored
and recorded weekly. Mouse weight and tumor sizes (di-
ameters) were periodically measured and lesion diame-
ters were converted to tumor volume using the following
formula: V = length ×width × height × 0.52. Tumor burden
of each individual mouse was calculated as the sum of its
individual tumour volumes. Twenty weeks after the DMBA
initiation, mice were anesthetized by intraperitoneal (i.p.)
injection of 2.5 % tribromoethanol (Sigma-Aldrich, St.
Louis, MO) and total blood was collected by axillary bleed-
ing from six animals of each genotype for the determin-
ation of VEGF, cleaved VEGFR1 and cleaved VEGFR2
concentrations. The remaining WT and Dll4+/− mice (n = 6
for each genotype) were perfused with biotin-conjugated
lectin (Sigma, St. Louis, MO), as described below, for the
assessment of tumor vessel functionality. The skin tumors
were then dissected from all WT and Dll4+/− mice and
processed for histological or molecular analyses.
Tumor tissue preparation, histopathology and
immunohistochemistry
Skin tumor samples were processed as previously de-
scribed [12] and cryosectioned at 20 μm. Sections
were stained with hematoxylin (FlukaAG Buchs SG,
Switzerland) and eosin Y Sigma Chemicals, St. Louis,
MO). Double fluorescent immunostaining to platelet
endothelial cell adhesion molecule (PECAM) and vas-
cular smooth muscle cell marker alpha smooth muscle
actin (α-SMA) was also performed on tumor tissue
sections to examine tumor vascular density and vessel
maturity. Rat monoclonal anti-mouse PECAM (BD
Pharmingen, San Jose, CA) and rabbit polyclonal anti-
mouse α-SMA (Abcam, Cambridge, UK) were used as
primary antibodies and appropriate species-specific
antibodies conjugated with Alexa Fluor 488 and 555
(Invitrogen, Carlsbad, CA) were engaged as secondary
antibodies. Nuclei were counterstained with 4′,6-
diamidino-2-phenylindole dihydrochloride hydrate
(DAPI; Molecular Probes, Eugene, OR). Fluorescent
immunostained sections were examined under a Leica
DMRA2 fluorescence microscope with Leica HC PL
Fluotar 10 and 20X/0.5 NA dry objective, captured
using Photometrics CoolSNAP HQ, (Photometrics,
Friedland, Denmark), and processed with Metamorph
4.6–5 (Molecular Devices Sunnyvale, CA). Morpho-
metric analyses were performed using the NIH ImageJ
1.37v program. To estimate vessel density, we
measured the percentage of tumor stroma surface oc-
cupied by a PECAM positive signal. Mural cell recruit-
ment was assessed as a measure of vascular maturity
by quantitating the percentage of PECAM-positive
structures lined by α- SMA-positive coverage. For the
assessment of VEGFR2 expression in papillomas, im-
munostaining was performed using purified rat anti-
mouse VEGFR2 (BD Pharmingen, San Jose, CA) and
appropriate secondary antibody conjugated with Alexa
Fluor 555 (Invitrogen, Carlsbad, CA). PDGFR-β ex-
pression was assessed by double PECAM/PDGFR-β
immunostaining for which we used rat monoclonal
anti-mouse PECAM (BD Pharmingen, San Jose, CA),
rabbit monoclonal anti-mouse PDGFR-β (Cell Signal-
ling Technology, Denver, MA), and appropriate sec-
ondary antibodies conjugated with Alexa Fluor 488
and 555 (Invitrogen, Carlsbad, CA). Papillomas from
WT and mutant mice were compared upon the meas-
urement of the percentage of tumor stroma surface
occupied by a VEGFR2 positive signal as well as the
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measurement of the percentage of PECAM-positive
structures lined by PDGFR-β-positive coverage.
Vessel perfusion study
To assess vascular perfusion and determine the functional
fraction of the tumor circulation, the anesthetized mice
were injected via caudal vein with a solution of biotin-
conjugated lectin from Lycopersicon esculentum (100 μg in
100 μl of PBS; Sigma, St. Louis, MO), which was allowed
to circulate for 5 min before transcardially perfusion with
4 % PFA in PBS for 3 min. Tumor samples were collected
and processed as described above. Tissue sections (20 μm)
were stained with rat monoclonal anti-mouse PECAM
antibody (BD Pharmingen, San Jose, CA), followed by
Alexa 555 goat anti-rat IgG (Invitrogen, Carlsbad, CA).
Biotinylated lectin was visualized with Strepatavidin-Alexa
488 (Invitrogen, Carlsbad, CA). The images were obtained
and processed as described above. Tumor perfusion was
quantified by determining the percentage of PECAM-
positive structures that co-localized with Alexa 488 signal,
corresponding to lectin-perfused vessels.
Serum VEGF, VEGFR1 and VEGFR2 measurement
Blood was allowed to clot during 45 min at 37 °C and
then centrifuged during 10 min at 1000 × g. VEGF,
VEGFR1 and VEGFR2 serum levels were measured by
enzyme-linked immunosorbent assay (ELISA; R&D Sys-
tems), as described [25].
Quantitative transcriptional analysis
Using a SuperScript III FirstStrand Synthesis Supermix
qRTPCR (Invitrogen, Carlsbad, CA), first-strand cDNA was
synthesized from total RNA previously isolated with
RNeasy Mini Kit (Qiagen, Valencia, CA) from skin tumors
developed by WT and Dll4+/− mice (n = 10 tumors for each
genotype). Real-time PCR analysis was performed as de-
scribed [26] using specific primers for β-actin, Dll4, Hey2,
PDGF-β, EphrinB2 and Tie2. Gene expression levels were
normalized to β-actin. Primer pair sequences are available
upon request.
Sorafenib therapy assay
For the evaluation of combined effect of Dll4 allelic deletion
and sorafenib administration, 8-week old WT and Dll4+/−
male mice were separated in two equal sub-groups for each
genotype (n = 4 for each of four experimental sub-groups)
and skin tumorigenesis was induced and promoted as
described above. Sorafenib was formulated twice a week at
4-fold (4×) concentration in a cremophor EL (Sigma, St.
Louis, MO)/ethanol 50:50 solution. The oral solutions were
prepared on the day of use by dilution to 1× with cremo-
phor EL/ethanol/water mixture (12.5:12.5:75). Beginning
13 weeks after DMBA induction, a sub-group of WT and a
sub-group of Dll4+/− mice was treated by oral gavage for
21 days with sorafenib (40 mg/kg/day) while the mice from
the remaining WT and Dll4+/− sub-groups received only
the vehicle (cremophor EL/ethanol/water 12.5:12.5:75 mix-
ture). Prior and during the treatments, the weight of all
mice and their skin tumors were measured once a week
and at the experiment endpoint when the mice were sacri-
ficed, tumors dissected and PECAM/α-SMA double immu-
nostaining performed as described above.
Statistical analyses
The sample size determination was empiric, based on pre-
vious experience [11, 12] and the occurrence of DMBA/
TPA-induced skin lesions in 100 % of CD1 WT mice. All
measurements in the study were independently performed
by two technicians who were blind to the group to which
the experimental animals belonged. For each measurement,
the average of values obtained by two technicians was taken
as the measurement result. Data processing was carried out
using the Statistical Package for the Social Sciences version
15.0 software (SPSS v. 15.0; Chicago, IL). Statistical ana-
lyses were performed using Mann–Whitney-Wilcoxon
test. All results are presented as mean ± SEM. P-values
<0.05 and <0.01 were considered significant (indicated in
the figures with *) and highly significant (indicated with
**), respectively.
Results and discussion
Dll4 allelic deletion promotes the growth of induced skin
papillomas
To study the Dll4/Notch function in mouse skin tumors
and evaluate the effect of its suppression, we monitored
skin lesion formation and evolution in WT and Dll4+/−
mice during 20 weeks. As presented in Fig. 1a, Dll4+/− mice
started developing skin tumors as early as week 6 after
DMBA-initiation and by week 10.5 of the study, 50 % of
Dll4+/− mice developed at least one lesion (tumor latency).
Tumor onset and latency were delayed in WTanimals for 2
and 1 week, respectively. Regarding tumor multiplicity, in-
creased number of lesions per mouse was observed in Dll4
+/− mice compared to WT controls throughout the experi-
ment, but without statistical significance. Importantly, we
observed a higher frequency of larger tumors, significantly
increased mean lesion volume and overall tumor burden
(calculated as the sum of tumor volumes per mouse) in
Dll4+/− relative to WT mice at the experiment endpoint;
p < 0.05 (Fig. 1a and b). Body weight of WT and Dll4+/−
mice did not change significantly at any time during the
course of the study, suggesting a low level of systemic car-
cinogen toxicity.
Histological analysis revealed that the two experimental
groups were uniform in terms of tumor histopathology,
presenting similar rates of malignant tumor conversion
(Table 1). DMBA alone can cause angiomatous lesions.
However they were neither observed in WT nor in Dll4
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+/− mice. With the exception of a single squamous cell
carcinoma (SSC), grade I, observed in each group, all
remaining skin alterations were exophytic lesions classi-
fied as benign squamous papillomas displaying hyperkera-
totic epidermal projections with foci of dyskeratosis and
dysplasia, intact basement membrane and superficial der-
mal inflammation (Fig. 1c). Thus, reduced Dll4/Notch sig-
naling does not necessarily prevent tumor growth. On the
contrary, in this case, in the context of chemically-induced
skin papillomas it did promote it. Dll4 allelic deletion
reduced papilloma latency and promoted their multiplicity
and growth, although without affecting malignant pro-
gression of these lesions.
Impaired Dll4/Notch signaling results in excessive, less
mature but productive angiogenic response in induced
skin tumors
To better understand the observed effect on tumor
growth of reduced Dll4/Notch signaling, we examined the
vascular morphology of the tumors derived from WT and
Dll4+/− mice. As presented in Fig. 2a, the WT papillomas
were found to be vascularized lesions characterized by
irregular vessel formation. However, the WT tumor vas-
culature presented high degrees of vessel maturity (Fig. 2b)
and functionality (Fig. 2c), as indicated by PECAM/α-
SMA and PECAM/lectin colocalization, respectively. In
comparison, Dll4+/− papillomas showed ~35 % increase in
vessel density, measured as the PECAM– positive area per
tumor stromal surface (p < 0.05, Fig. 2a), forming more
disorganized endothelial networks with pronounced
A
B C
Fig. 1 Dll4 allelic deletion promotes the onset and growth of chemically- induced skin tumors. a Tumor kinetics in DMBA/TPA-treated WT and
Dll4+/− mice. b Representative WT and Dll4+/− mouse 20 weeks after DMBA-initiation. c Hematoxylin and eosin staining of a squamous papilloma
sampled from a Dll4+/− mouse
Table 1 Histopathological analysis of lesions from DMBA/TPA-
treated wild type and Dll4+/− mice
Diagnosis Wild-type Dll4+/−
Squamous papilloma 68 112
SCC grade I 1 1
Total 69 113
Results shown are from 182 lesions from WT and Dll4+/− littermates (n = 12 for
each group) treated with a single initiation dose of 25 μg DMBA followed by
4 μg TPA twice a week for 19 weeks. SSC squamous cell carcinoma
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branching and thin interconnections (data not shown). In
addition, α-SMA–positive cells lining PECAM–positive
endothelium were significantly reduced (31 % reduction,
p < 0.05, Fig. 2b), a sign of impaired vessel maturation.
However, despite the reduced luminal diameters and
impaired vessel wall assembly in Dll4+/− papillomas rela-
tive to the WT mouse lesions (data not shown), the frac-
tion of lectin-perfused vessels, i.e. functional vessels, was
not significantly altered (<10 %, Fig. 2c), which means the
mutant mice had more functional tumor vessels in abso-
lute terms, given the increased vessel density they dis-
played. Thus, the 50 % reduction of Dll4 function allowed
competent neovessel formation and is likely to be respon-
sible for the increase in papilloma growth. Our results ini-
tially appear contradictory to substantial data showing
that the Dll4/Notch blockade inhibits functional angio-
genesis, yet in this case a genetic modification that lowers




Fig. 2 Partial Dll4/Notch inhibition due to haploid Dll4 deletion enhances less mature but productive angiogenesis in skin papillomas. a Vascular
response examined by PECAM immunostaining indicating increased sprouting and network disorganization with reduced vessel calibers in Dll4+/− vs.
WT mice. b Mural cell coverage examined by double immunostaining of PECAM and α-SMA showing reduced recruitment of perivascular cells in Dll4
+/− tumors. c Tumor vessel competence evaluated by lectin perfusion and subsequent double staining to PECAM and biotinylated lectin demonstrating a
reduction in the fraction of perfused vessels in Dll4+/− vs. WT mice
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regard to the number of vessels, however, the effects are
comparable with the Dll4/Notch inhibition in invasive tu-
mors, as Dll4 heterozygozity also increased vessel density
in our experiments. The difference relates to the func-
tionality of the newly-formed vessels.
Dll4 down-regulation increases VEGFR function in the skin
papillomas
We propose that the different effects of reduced
Dll4 expression on vascular functionality in early vs.
late tumors are determined by the background level
of VEGF and VEGF/VEGFR signaling. Dll4 heterozy-
gozity was expected to reduce Vegfr1 expression and
increase Vegfr2 expression [6], which could account
for the increase in angiogenesis and growth of the
Dll4+/− tumors. We assessed the levels of expression
by measurement of cleaved VEGFR1 and VEGFR2 in
the serum collected at the end of the experiment,
when the tumor bulk was maximal. We detected a
marked and statistically significant increase in the
serum VEGFR2/VEGFR1 ratio in the Dll4+/− mice
(Fig. 3a), implying increased endothelial sensitivity to
VEGF and enhanced VEGF signaling in Dll4+/− pap-
illomas. We also investigated VEGF serum levels but
found no difference in the two groups of animals.
Nevertheless, with papilloma VEGFR2 immunostain-
ing, we demonstrated, as expected, its highly signifi-
cant increase in the vasculature of Dll4+/− vs. WT
lesions (Fig. 3b).
In the context of VEGF levels, which are increased in
papillomas, but not as much as in invasive tumors [27],
normal Dll4/Notch signaling levels act as a suppressor of
VEGF signaling and even a 50 % decrease can result in a
change of VEGFR2/VEGFR1 ratio and marked increase in
responsiveness to VEGF levels. However, in the context of
very high levels of VEGF, Dll4/Notch signaling is likely to
be essential to prevent excessive proliferation, aberrant
vessel structure and leakiness. So in this case unrestrained
VEGF function is detrimental to the functionality of the
tumor vascular network. The effects of Angiopoietin-1
(Ang-1) and Angiopoietin-2 (Ang-2) interacting on the
Tie2 receptor share some similarity with our findings. An-
tagonism of Ang-1 by Ang-2 dissociates perivascular cell
coverage, and then in the absence of VEGF vessels regress,
but in the presence of VEGF, endothelium becomes acti-
vated and vessels proliferate [28]. The level of VEGF is
critical for the effect of the antagonistic pathway.
Similarly, Dll4/Notch blockade enhances EC activation
and allows a large number of small vessels to grow,
but against the background of very high VEGF levels
in invasive tumors these fail to become productive
while in the background of lower VEGF levels in be-
nign/early lesions they become functional.
Dll4 deletion affects the expression of factors regulating
perivascular cell recruitment in chemically-induced skin
papillomas
Although Dll4 haploinsufficiency was found to promote
productive angiogenesis in this model, it did indeed nega-
tively influence perivascular cell recruitment to the prolif-
erating tumor capillaries. Thereby, we next used qRT-PCR
to analyze WT and Dll4+/− papillomas for differential ex-
pression of genes known to be involved in EC/ vascular
smooth muscle cell interactions (Fig. 3c). We observed
that Dll4+/− tumors had ~2-fold lower Dll4 mRNA levels
and down-regulated Hey2 expression in comparison to
WT, confirming the Notch pathway suppression. Both the
angiopoietin receptor Tie2 [29, 30] and EphrinB2 [31]
were downregulated upon Dll4 allelic deletion, which
could account for impaired mural cell recruitment in the
Dll4+/− papillomas. Since the observation of increased
Pdgfr-β mRNA levels was counterintuitive, we performed
PDGFR-β immunostaining. In contrast to the whole
tumor PDGFR-β increase, we documented its down-
regulation in Dll4+/− vessels, i.e. reduced PDGFR-β+
coverage of PECAM+ structures in Dll4+/− vs. WT mice
(Fig. 3d), which is in accordance with reduced perivascular
cell recruitment in mutant mouse papillomas.
Partially inhibited Dll4/Notch signaling decreases the tumor
suppressive effect of sorafenib on chemically-induced skin
tumors
Considering that Dll4 allele deletion changes the VEGFR
function in papillomas, we finally examined the influence of
Dll4 downregulation on the efficacy of sorafenib, an oral
small-molecule-receptor tyrosine kinase inhibitor which
targets include the VEGF receptors [32]. Sorafenib acts
either directly on the tumors by inhibiting Raf and Kit sig-
naling, and/or indirectly by suppressing tumor angiogenesis
through the inhibition of VEGFR and PDGFR signaling
[33] (BAY 43–9006, Nexavar), a dual-action inhibitor that
targets RAF/MEK/ERK pathway in tumor cells and tyrosine
kinases VEGFR/PDGFR in tumor vasculature). Beginning
at week 13 after the DMBA-initiation, when all mice had
developed at least one skin lesion and approached the
exponential tumor-growth phase, we established 4 experi-
mental groups: Dll4+/− treated and control, WT treated and
control (Fig. 4a). Control animals received cremophor EL/
ethanol/water 12.5:12.5:75 mixture, the sorafenib vehicle,
and the treated received sorafenib at 40 mg/kg/day for
3 weeks. Comparing initial and final tumor volumes
(Fig. 4b), we observed that vehicle-treated WT tumors
showed a 2.1-fold volume increase over the period of
3 weeks while vehicle-treated Dll4+/− papillomas presented
a more pronounced 2.6-fold volume expansion (p <0.05).
On the other hand, sorafenib treatment effectively con-
tained tumor growth in WT animals, causing an average
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regression of 56 % (p < 0.05) of tumor volume, after the
3 week administration period. In strike contrast, Dll4+/−
skin lesions continued to progress despite the sorafenib
treatment, although the drug application provided a
marked tumor growth retardation compared to vehicle-
treated Dll4+/− papillomas. Interestingly, vehicle treated
WT and sorafenib-treated Dll4+/− mice presented very
comparable tumor volumes at the treatment endpoint, in-
dicating that 50 % Dll4/Notch inhibition virtually neutral-
ized the effects of sorafenib.
Upon Dll4/Notch inhibition, the papillomas became
more sensitive to VEGF due to increased VEGFR function
and less responsive to therapeutic VEGFR inhibition. In
comparison with sorafenib-treated WT mice, Dll4+/− mice
Fig. 3 Dll4 allele deletion affects VEGF/VEGFR signaling and the regulators of vascular smooth muscle cell recruitment. a Average serum level of
VEGF, VEGFR1, VEGFR2 measured by ELISA and VEGFR2/VEGFR1 (R2/R1) ratio in WT and Dll4+/− mice. Between two experimental groups, only
VEGFR2/VEGFR1 ratio (R2/R1) differs with statistical significance. b VEGFR2 immunostaining showing increased expression of this VEGF-A receptor
in Dll4+/− vs. control tumors. c Differential gene expression in WT vs. Dll4+/− papillomas determined by quantitative RT-PCR analyses. d Double
PECAM/PDGFR-β immunostaining showing reduced PDGFR-β+ vascular coverage and indicating reduced Pdgfr-β expression in the vasculature of
Dll4+/− vs. WT papillomas
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treated with this drug presented increased papilloma vas-
cular density, while combined Dll4 allele deletion and so-
rafenib application enhanced inappropriate perivascular
cell recruitment (Fig. 4c). Decreased efficacy of tyrosine
kinases inhibitors might also occur and be even more
pronounced in invasive lesions with high VEGF levels.
However, the effect on the efficacy of VEGF inhibitors is
likely to change with the degree of Dll4/Notch inhibition.
More pronounced Dll4/Notch suppression than that ob-
served in Dll4+/− mice, might increase their efficacy since
the abolishment of Dll4 function promotes unproductive
vascular response while concomitant VEGF/VEGFR2 inhib-
ition will reduce the rate of endothelial proliferation. Such
an outcome was previously observed with combinational
blockade of Dll4/Notch signaling, reducing vascular com-
petence, and EphrinB2 signaling, reducing endothelial pro-
liferation [12], presumably by interfering with the VEGFR
trafficking [34].
Conclusions
The role of Dll4 differs in early and late tumor develop-
ment. In early papillomas, lower levels of Dll4 increase
vascularization through change in VEGFR2 levels and
consequently enhance sensitivity to endogenous levels of
VEGF. In large invasive cancers that produce greater con-
centrations of VEGF, downregulation of VEGFR2 by Dll4/
Notch signaling is critical to maintain some degree of nor-
mal vascular function and organization, and therefore a
loss of this buffering mechanism results in excessive vessel
sprouting with overall loss of vascular function and tumor
perfusion. These observations may be relevant to patients
who go onto long term anti-Dll4 therapy, which may be
used chronically as is anti-VEGF therapy.
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Fig. 4 Dll4 deletion reduces sorafenib efficacy against DMBA/TPA-
mediated skin papillomas. a Treatment schematic diagram. b Tumor
volume changes in WT and Dll4+/− mice during the treatment with
vehicle or sorafenib. c Vascular response examined by double PECAM/
α-SMA immunostaining indicating reduced sprouting and recruitment
of perivascular cells in sorafenib-treated vs. vehicle-treated WT mice, as
well as enhanced endothelial proliferation, however, with increasingly
impaired vessel wall assembly in sorafenib-treated Dll4+/− vs. WT mice
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